Questions
Straight answers,
including the limits.
What Terrane covers, where the facts come from, how to check them, and what is not built yet.
Last updated 2026-07-26
What it is
- What is Terrane?
- Terrane is a life sciences landscape intelligence product. It maps companies, programs, clinical trials, investors and partnerships as one connected picture, organized by indication, mechanism of action, modality, clinical phase and licensing status. Every relationship it records keeps the source it came from and the sentence it was read out of, so any answer can be traced back to a document.
- What is life sciences landscape intelligence?
- Life sciences landscape intelligence is the practice of holding an entire therapeutic field as one connected, sourced picture rather than as separate records. It answers questions about a whole field: who is developing against a target, how far along they are, who financed them, and what happened to the programs that came before. It replaces landscape research that is otherwise assembled by hand.
- Is Terrane only for deals?
- No. Terrane answers landscape and research questions as readily as deal questions. Which companies are developing for an indication, which trials are running against a mechanism, who has treated a condition before and what happened to those programs are all first-class questions here. Deal questions are one use of the same map, not the boundary of what it covers.
- Can I research a single company, or only a whole field?
- Both, from the same map. Open a single company in Terrane and you get its programs, trials, financing history, investors and partners on one page with citations. Open an indication and you get everyone working in it. The two are the same underlying record at different zoom levels, so moving between them does not mean changing tools.
Coverage and data
- Where does Terrane get its data?
- Terrane reads public primary sources: clinical trial registries including ClinicalTrials.gov, regulatory filings, the biopharma trade press, and company releases. Nothing is licensed from a proprietary panel, which is why every fact can be shown with the document behind it. The value is in the assembly and the connections, not in exclusive access to data nobody else can see.
- Does it cover modalities other than small molecules?
- Yes. Modality is a first-class field in Terrane, not an afterthought, so biologics, cell and gene therapies, RNA, peptides, radioligands and device-drug combinations are all modeled as such. A landscape that only handled small molecules would misrepresent most therapeutic areas, and would miss competing approaches filed under a different label.
- Does it include programs that failed?
- Yes, and deliberately. Terrane keeps discontinued and terminated programs in the record rather than dropping them. The most useful answer to "has anyone tried this before" is often that they have, and here is where it stopped. A landscape that only shows live programs is a misleading one, particularly in diligence.
- How current is it?
- Terrane updates as evidence is published rather than on a fixed refresh schedule. New financings, readouts, licensing deals and program changes enter the map as they appear in the sources, and the map accumulates rather than being rebuilt, so history is preserved alongside what is current.
- Does it cover private companies?
- Yes. Private companies are central to the picture in life sciences, so Terrane treats them the same as public ones: programs, trials, financings, investors and partnerships, drawn from trial registries, the trade press and company announcements. Filings add depth where a company is public or has filed to go public.
Trust and method
- How do I verify a fact I find?
- Every relationship in Terrane stores the source URL and the exact sentence the fact was extracted from, and both are visible on the fact itself rather than in a general bibliography. That means an answer several steps into a line of research is still one you can defend line by line in front of an investment committee or a board.
- Does it use AI, and how do you stop it inventing things?
- Yes. Terrane uses language models to read source documents and record what they say into a fixed set of life sciences fields, never to write prose that is then treated as fact. Every recorded fact keeps the document and the sentence behind it, and anything the software is unsure about goes to a person before it becomes part of the record. The model reads sources; it does not author facts.
- How is this different from a pipeline or clinical trial database?
- Pipeline and trial databases are organized around one kind of record and answer questions about that record extremely well. Landscape questions cross domains: which investors backed programs against this mechanism, which assets in this indication have no partner, what happened to the last three attempts. Answering those from single-domain tools means licensing several and joining them by hand.
- How is this different from a generalist deal database?
- Generalist databases classify a biotech by an industry tag, because they are built to serve every sector at once. In Terrane the dimensions that determine value in life sciences are the data model itself: indication, mechanism of action, modality, clinical phase, and partnership and licensing status.
Access
- Who is Terrane for?
- Terrane is built for business development and corporate development teams, competitive intelligence and corporate strategy groups, clinical development and medical affairs, life sciences investors, and founders. What they have in common is asking questions about a field rather than a single record, and needing to show their sources afterwards.
- Can I use it now, and what does it cost?
- Terrane is pre-launch. Early access is open by request, and a first cohort is being onboarded now. Pricing has not been set publicly. All figures shown across this site are illustrative placeholders rather than live product data, and are labeled as such wherever they appear.
Longer background on the category, the sources it is built from, and the other tools in this market: What is landscape intelligence →
Ask us something else.
Join the early access list and tell us the indications you cover. We answer questions from the list directly.